NDLI: Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Content Provider	Springer Nature : BioMed Central
Author	Qian, Wenjing Zhao, Mingfang Wang, Ruoyu Li, Heming
Abstract	Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line monotherapies in certain tumor types. However, the efficacy of anti-PD-1/PD-L1 mAbs is still limited due to toxic side effects and de novo or adaptive resistance. Moreover, other immune checkpoint target and biomarkers for therapeutic response prediction are still lacking; as a biomarker, the PD-L1 (CD274, B7-H1) expression level is not as accurate as required. Hence, it is necessary to seek more representative predictive molecules and potential target molecules for immune checkpoint therapy. Fibrinogen-like protein 1 (FGL1) is a proliferation- and metabolism-related protein secreted by the liver. Multiple studies have confirmed that FGL1 is a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3), emphasizing the potential of targeting FGL1/LAG3 as the next generation of immune checkpoint therapy. In this review, we summarize the substantial regulation mechanisms of FGL1 in physiological and pathological conditions, especially tumor epithelial to mesenchymal transition, immune escape and immune checkpoint blockade resistance, to provide insights for targeting FGL1 in cancer treatment.
Related Links	https://jhoonline.biomedcentral.com/counter/pdf/10.1186/s13045-021-01161-8.pdf
Ending Page	17
Page Count	17
Starting Page	1
File Format	HTM / HTML
ISSN	17568722
DOI	10.1186/s13045-021-01161-8
Journal	Journal of Hematology & Oncology
Issue Number	1
Volume Number	14
Language	English
Publisher	BioMed Central
Publisher Date	2021-09-15
Access Restriction	Open
Subject Keyword	Oncology Hematology Cancer Research FGL1 LAG-3 Biomarker Immune resistance Immune checkpoint blockade
Content Type	Text
Resource Type	Review
Subject	Hematology Cancer Research Oncology Molecular Biology
Journal Impact Factor	29.9/2023
5-Year Journal Impact Factor	27.1/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating MYC-target genes.

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Tim-3 expression and its role in hepatocellular carcinoma

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade

Next generation of immune checkpoint inhibitors and beyond

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Similar Documents

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating MYC-target genes.

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Tim-3 expression and its role in hepatocellular carcinoma

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade

Next generation of immune checkpoint inhibitors and beyond

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target